Jonathan E Mcdunn

US Patent:

8143222, Mar 27, 2012

Filed:

Oct 22, 2008

Appl. No.:

12/255947

Inventors:

Jonathan E. McDunn - University City MO, US
William G. Hawkins - Olivette MO, US
Robert H. Mach - Eureka MO, US
Richard A. Hotchkiss - Chesterfield MO, US

Assignee:

Washington University - Saint Louis MO

International Classification:

A61K 38/02
A61K 38/16
C07K 2/00
C07K 14/00

US Classification:

514 189, 514 193, 514 213, 514 214, 530324, 530326, 530345, 530402

Abstract:

Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant Kof less than about 10M, and a pharmaceutically active moiety, wherein the targeting moiety is other than an oligopeptide, a polypeptide, a peptidomimetic, a protein or a protein domain, and wherein the targeting moiety and the pharmaceutically active moiety are covalently attached. In some aspects, the targeting moiety binds a sigma-2 receptor with high affinity and high specificity, and the pharmaceutically active moiety is a pro-apoptotic peptide moiety. Methods of cancer treatment are disclosed comprising administering a disclosed pharmaceutical compound to a subject in need of thereof. The treatments selectively induce apoptosis in cancer cells. These methods can further comprise co-administration of radiation therapy and/or an additional chemotherapeutic agent.

US Patent:

20060166881, Jul 27, 2006

Filed:

Nov 23, 2005

Appl. No.:

11/286920

Inventors:

Richard Hotchkiss - Chesterfield MO, US
David Piwnica-Worms - Ladue MO, US
Jonathan McDunn - University City MO, US

International Classification:

A61K 48/00
C07K 14/475

US Classification:

514012000, 514044000, 530352000

Abstract:

Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided.

US Patent:

20060263382, Nov 23, 2006

Filed:

Mar 29, 2006

Appl. No.:

11/391964

Inventors:

Richard Hotchkiss - Chesterfield MO, US
David Piwnica-Worms - Ladue MO, US
Jonathan McDunn - University City MO, US

International Classification:

A61K 39/00

US Classification:

424185100

Abstract:

Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.

US Patent:

20090012025, Jan 8, 2009

Filed:

Feb 11, 2008

Appl. No.:

12/029412

Inventors:

Richard Hotchkiss - Chesterfield MO, US
Jonathan McDunn - University City MO, US
David Piwnica-Worms - St. Louis MO, US
Steven Schwulst - St. Louis MO, US

International Classification:

A61K 31/7105
A61P 31/04

US Classification:

514 44

Abstract:

Methods of treatment of sepsis are disclosed. These methods comprise administering to a subject a composition comprising at least one siRNA directed against at least one gene encoding a pro-apoptotic polypeptide. The pro-apoptotic polypeptide, in some aspects, can be other than Fas or caspase-8. In some embodiments, an siRNA can be directed against a pro-apoptotic component of the mitochondrial pathway, such as a pro-apoptotic bcl-2 protein. In some aspects, an siRNA can be directed against a BH3-only bcl-2 protein, while in other aspects, siRNAs can be directed against multi BH domain Bcl-2 family members such as bax and bak. In some embodiments, an siRNA can be directed against a death receptor pathway molecule such as FADD. In various configurations, a composition can also comprise a cationic lipid such as DOTAP, or nanoparticles comprising a cyclodextrin-containing polycation and a polymer such as a poly(ethylene glycol).

US Patent:

20100121031, May 13, 2010

Filed:

Nov 12, 2009

Appl. No.:

12/617561

Inventors:

Richard Hotchkiss - Chesterfield MO, US
David Piwnica-Worms - Ladue MO, US
Jonathan McDunn - University City MO, US

Assignee:

WASHINGTON UNIVERSITY - St. Louis MO

International Classification:

C07K 14/435

US Classification:

530350

Abstract:

Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.

US Patent:

20130217647, Aug 22, 2013

Filed:

Jul 27, 2011

Appl. No.:

13/812183

Inventors:

Jeffrey R. Shuster - Chapel Hill NC, US
Matthew W. Mitchell - Durham NC, US
Jonathan E. McDunn - Cary NC, US
Bruce Neri - Cary NC, US

Assignee:

METABOLON, INC. - Durham NC

International Classification:

G01N 33/574
A61K 31/7072
A61K 31/685

US Classification:

514 51, 436501, 435 792, 435 71, 514114

Abstract:

Biomarkers (and suites of biomarkers) relating to prostate cancer are provided, as well as methods for using such biomarkers (ans suites thereof), including early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy.

US Patent:

20210137970, May 13, 2021

Filed:

Nov 5, 2020

Appl. No.:

17/090637

Inventors:

- Durham NC, US
Jonathan Edward McDunn - Cary NC, US

International Classification:

A61K 33/00
A61K 9/16
A61L 31/16
A61L 31/10
A61L 31/12
A61L 31/06
C08K 9/04
C08K 5/22
C08K 3/36

Abstract:

Methods of preparing nitric oxide-releasing silica particles are provided, including the steps of functionalizing a silica particle with a linker moiety; and reacting a functional group on a nitric oxide storage/release compound with the linker moiety to attach the nitric oxide storage/release compound to the silica particle via the linker moiety. The disclosure also provides certain nitric oxide-releasing silica particles and precursors thereof, as well as compositions containing such particles.